In the randomized, double-blind, phase 3 study, experts explored treatment with neoadjuvant pembrolizumab (Keytruda) plus chemotherapy, followed by adjuvant pembrolizumab, in patients aged 18 years ...

The KEYNOTE-689 study evaluating pembrolizumab in this patient population met its primary end point of event-free survival.

First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended by NICE ...

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab yields a significant improvement in overall survival ...

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in ...

Oncologists never know which patients with dire prognoses will be among the rare, but real responders. The few who defy all ...

This emphasizes a critical issue as pembrolizumab is increasingly being used in early TNBC and could have long-term survivorship implications. Supported in part by The University of Texas MD Anderson ...

ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, today announced that it has entered into a ...

The imaging agent Gleolan is only approved for glioma surgery, so the current trial could lead to a new indication. In this ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...